Elekta (EKTA) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
29 Apr, 2026Executive summary
Net sales at constant exchange rates grew by 2% year-over-year, driven by strong order intake and commercial momentum in Europe and China, while reported sales in SEK declined by 10% due to currency effects.
Book-to-bill ratio improved to 1.17 for Q3, reflecting robust order growth in China, the U.S., and Europe.
Significant restructuring underway, with SEK 417 million charge in Q3 and over 80% of planned changes executed; annual cost savings expected to exceed SEK 500 million with full impact from Q1 next year.
Product launches, notably Elekta Evo with U.S. approval in January, supported margin improvement and commercial execution.
Net income dropped to SEK 12 million (from SEK 336 million), with EPS at SEK 0.03 (from SEK 0.89), impacted by restructuring charges and FX.
Financial highlights
Net sales increased by 2% year-over-year in constant currency, reaching SEK 4,239 million; solution sales up 1%, service up 3%.
Adjusted gross margin improved to 38.3% (from 37.1%), despite negative impacts from tariffs (100 bps) and FX (130 bps).
EBIT margin at 11.9% (up from 11.7%); adjusted EBIT was SEK 504 million.
Cash flow after continuous investments was SEK 255 million for Q3, with year-to-date improvement of SEK 443 million; net debt decreased to SEK 3,819 million.
Adjusted EPS was SEK 0.88 (down from SEK 0.94 year-over-year).
Outlook and guidance
Full-year 2025/26 outlook reiterated: net sales in constant currency expected to grow year-over-year.
Continued negative impact from FX and tariffs anticipated in Q4 and beyond.
Midterm targets confirmed, including gross margin returning to pre-pandemic levels and EBIT margin reaching 14% or higher.
Guidance for China: double-digit growth (~10%) in both orders and revenue for H2.
Full run-rate cost savings from restructuring expected in Q1 2026/27.
Latest events from Elekta
- Four strategic priorities and a new model target SEK 500M+ savings and global growth.EKTA
Strategy update9 Apr 2026 - Sales up 5% year-over-year, but Q4 declined; margin recovery expected in H2 2024/25.EKTA
Q4 23/2431 Jan 2026 - Net sales up 1% with strong U.S. growth and a major Mexico order; margin recovery expected.EKTA
Q1 24/2523 Jan 2026 - Sales and margins declined, but new products and cost savings are set to boost performance.EKTA
Q2 24/2512 Jan 2026 - AI-driven adaptive radiotherapy and software boost growth, margins, and global adoption.EKTA
Investor update10 Jan 2026 - Record cash flow and European growth offset US and China weakness; margin guidance lowered.EKTA
Q3 24/2527 Dec 2025 - Margins improved, cash flow strengthened, and major cost-saving actions launched.EKTA
Q2 25/2626 Nov 2025 - Net sales up 3% in constant currency, margins down, net income up 50%, cash flow improved.EKTA
Q1 25/2623 Nov 2025 - Margin expansion, software growth, and profitable orders drive confidence in mid-term targets.EKTA
Investor update21 Nov 2025